Dantrolene

Evidence Level: L5

Predicted Indications: 7

Dantrolene

Pharmacist Assessment Report

Dantrolene: ryanodine receptor (RyR1) inhibitor → moderate multiminicore disease with hand involvement

One-Sentence Summary

Dantrolene is an oral skeletal muscle ryanodine receptor inhibitor that is currently marketed in Australia. The TxGNN model predicts it may be relevant to moderate multiminicore disease with hand involvement, with a score of 0.9990. There are currently no clinical trials and no publications in the data compiled for this report that directly support this prediction, so it rests on the model output alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	moderate multiminicore disease with hand involvement
TxGNN Prediction Score	0.9990
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for dantrolene is not available in the data compiled for this report. Dantrolene is generally understood to act on the skeletal muscle ryanodine receptor (RyR1), which controls calcium release from the sarcoplasmic reticulum.

The high prediction score is likely driven by proximity to the RYR1 gene in the TxGNN network. Multiminicore disease is a congenital myopathy, and some forms are linked to calcium-handling pathways in skeletal muscle. This makes a mechanistic connection plausible in principle.

However, there is no direct evidence that dantrolene has any effect in this condition. The mechanistic link is a hypothesis generated by the model, not a finding from clinical or laboratory studies. The route and formulation compatibility, and the similarity to the drug’s established use, have not yet been assessed.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
1779P	Dantrium	Capsule containing dantrolene sodium hemiheptahydrate 25 mg	Not recorded in the local data

The local data shows one valid single-ingredient licence and no cancelled licences. The only route recorded is oral.

Safety Considerations

Drug Interactions: The interaction screen returned 72 interacting drugs in total. The 20 entries below are those compiled for this report.

Major: morphine, morphine (liposomal)
Moderate: dronabinol, metoclopramide, nabilone, naltrexone, opium, sibutramine, ethanol, promethazine
Severity unknown: pantoprazole, metformin, omeprazole, lansoprazole, simvastatin, ranitidine, famotidine, glipizide, clarithromycin, clopidogrel

Most of the listed moderate and major interactions involve other central nervous system depressants or sedating agents. Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by a high model score. There are no clinical trials, no publications, and no direct evidence of a dantrolene effect in this condition, so the evidence level is L5.

To proceed, the following is needed:

A systematic literature search for any direct data on dantrolene in multiminicore disease, including hand-involvement phenotypes
Mechanism of action data and a documented mechanistic rationale linking RyR1 modulation to this condition
Review of the TGA-approved PI for warnings and contraindications, particularly liver and muscle-related considerations
Assessment of route and formulation compatibility with the proposed use
Evidence of clinical benefit, such as preclinical models or case series, before any trial design is considered
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.